Abstract:Macrophages are important effector cells in inflammatory responses. They are involved in bacterial infections and autoimmune diseases but also in the low grade inflammation associated with obesity and metabolic syndrome. Macrophages also have homeostatic functions and they activate healing process associated with inflammation and tissue injury [1-3]. To achieve these multiform tasks, macrophages are programmed to display distinct phenotypes in response to environmental signals [2-5]. For example, Th1 cytokine interferon γ (IFNγ) and toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) trigger classical, i.e. type M1, activation of macrophages, which is typical for bacterial infections and autoimmune reactions [6]. On the other hand, Th2 cytokines interleukin (IL) 4 and 13 trigger alternative, i.e. type M2, activation, which is associated with wound healing but also with the aberrant immune responses associated with overactivation of fibroblasts and subsequent fibrosis [6,7]. Classical activation of macrophages leads to the release of proinflammatory and antimicrobial factors including IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) pathway. On the other hand, alternatively activated macrophages express factors that have been associated with recognition of extracellular pathogens and/or stimulation of fibroblasts. Some of Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with Research Article Open Access

Control of Macrophage Activation and Function by PPARs

Peroxisome Proliferator-Activated Receptor A/G Reprogrammes Metabolism Associated with Lipid Accumulation in Macrophages

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

PPARs/macrophages: A Bridge Between the Inflammatory Response and Lipid Metabolism in Autoimmune Diseases

Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

Function of PPAR-γ and Related Signaling Pathways

PPAR control of metabolism and cardiovascular functions

Omega-3 Polyunsaturated Fatty Acids Antagonize Macrophage Inflammation Via Activation of Ampk/Sirt1 Pathway

PPARs: the vasculature, inflammation and hypertension:

Modulation Of Peroxisome Proliferator-Activated Receptor Gamma (Ppar Gamma) By Conjugated Fatty Acid In Obesity And Inflammatory Bowel Disease

Control of macrophage metabolism and activation by mTOR and Akt signaling

Regulation of Immune Cell Function by PPARs and the Connection with Metabolic and Neurodegenerative Diseases

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

Arachidonic Acid Metabolism Controls Macrophage Alternative Activation Through Regulating Oxidative Phosphorylation in PPAR Dependent Manner

Posttranslational Modifications of Peroxisome Proliferator-activated Receptor γ

Arachidonic Acid Metabolism Controls Macrophage Alternative Activation Through Regulating Oxidative Phosphorylation in PPARγ Dependent Manner

Advance on PPAR-γ Function

Homeostatic Ppar Alpha Signaling Limits Inflammatory Responses To Commensal Microbiota In The Intestine

Temporal Effects Of Peroxisome Proliferator-Activated Receptor. Activation On Macrophage Inflammatory Responses

PPARs as Nuclear Receptors for Nutrient and Energy Metabolism

PPAR-gamma agonists as regulators of microglial activation and brain inflammation